메뉴 건너뛰기




Volumn 15, Issue 5, 2014, Pages 257-268

Pharmacological management of cardiovascular conditions and diabetes in older adults with HIV infection

Author keywords

Antiretrovirals; Cardiovascular disease; Diabetes; Drug interactions; HIV

Indexed keywords

ABACAVIR; ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DARUNAVIR PLUS RITONAVIR; DIPYRIDAMOLE; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; ETRAVIRINE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; MARAVIROC; MEVINOLIN; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; SAQUINAVIR; SIMVASTATIN; UNINDEXED DRUG;

EID: 84897426889     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12116     Document Type: Review
Times cited : (12)

References (80)
  • 1
    • 84855343477 scopus 로고    scopus 로고
    • Projected life expectancy of people with HIV according to timing of diagnosis
    • Nakagawa F, Lodwick RK, Smith CJ etal. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26: 335-343.
    • (2012) AIDS , vol.26 , pp. 335-343
    • Nakagawa, F.1    Lodwick, R.K.2    Smith, C.J.3
  • 2
    • 0038714245 scopus 로고    scopus 로고
    • Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients
    • Barbaro G, Klatt EC. Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients. Curr Pharm Des 2003; 9: 1475-1481.
    • (2003) Curr Pharm Des , vol.9 , pp. 1475-1481
    • Barbaro, G.1    Klatt, E.C.2
  • 3
    • 0036840147 scopus 로고    scopus 로고
    • Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel
    • Schambelan M, Benson CA, Carr A etal. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31: 257-275.
    • (2002) J Acquir Immune Defic Syndr , vol.31 , pp. 257-275
    • Schambelan, M.1    Benson, C.A.2    Carr, A.3
  • 4
    • 33750994354 scopus 로고    scopus 로고
    • Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients
    • Orlando G, Meraviglia P, Cordier L etal. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med 2006; 7: 549-557.
    • (2006) HIV Med , vol.7 , pp. 549-557
    • Orlando, G.1    Meraviglia, P.2    Cordier, L.3
  • 5
    • 72849128722 scopus 로고    scopus 로고
    • Coronary aging in HIV-infected patients
    • Guaraldi G, Zona S, Alexopoulos N etal. Coronary aging in HIV-infected patients. Clin Infect Dis 2009; 49: 1756-1762.
    • (2009) Clin Infect Dis , vol.49 , pp. 1756-1762
    • Guaraldi, G.1    Zona, S.2    Alexopoulos, N.3
  • 6
    • 34250671221 scopus 로고    scopus 로고
    • Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease
    • Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-2512.
    • (2007) J Clin Endocrinol Metab , vol.92 , pp. 2506-2512
    • Triant, V.A.1    Lee, H.2    Hadigan, C.3    Grinspoon, S.K.4
  • 7
    • 67649403401 scopus 로고    scopus 로고
    • Metabolic abnormalities associated with HIV infection and antiretroviral therapy
    • Fichtenbaum CJ. Metabolic abnormalities associated with HIV infection and antiretroviral therapy. Curr Infect Dis Rep 2009; 11: 84-92.
    • (2009) Curr Infect Dis Rep , vol.11 , pp. 84-92
    • Fichtenbaum, C.J.1
  • 8
    • 77953365087 scopus 로고    scopus 로고
    • Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection
    • Moyle G, Moutschen M, Martínez E etal. Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection. AIDS Rev 2010; 12: 3-14.
    • (2010) AIDS Rev , vol.12 , pp. 3-14
    • Moyle, G.1    Moutschen, M.2    Martínez, E.3
  • 9
    • 0032551258 scopus 로고    scopus 로고
    • Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
    • Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 1881-1883.
    • (1998) Lancet , vol.351 , pp. 1881-1883
    • Carr, A.1    Samaras, K.2    Chisholm, D.J.3    Cooper, D.A.4
  • 11
    • 84871234436 scopus 로고    scopus 로고
    • Inflammation, coagulation and cardiovascular disease in HIV-infected individuals
    • Duprez DA, Neuhaus J, Kuller LH etal. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS ONE 2012; 7: e44454.
    • (2012) PLoS ONE , vol.7
    • Duprez, D.A.1    Neuhaus, J.2    Kuller, L.H.3
  • 12
    • 73549088748 scopus 로고    scopus 로고
    • Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study
    • Obel N, Farkas DK, Kronborg G etal. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study. HIV Med 2010; 11: 130-136.
    • (2010) HIV Med , vol.11 , pp. 130-136
    • Obel, N.1    Farkas, D.K.2    Kronborg, G.3
  • 13
    • 75649093029 scopus 로고    scopus 로고
    • Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study
    • Worm SW, Sabin C, Weber R etal. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318-330.
    • (2010) J Infect Dis , vol.201 , pp. 318-330
    • Worm, S.W.1    Sabin, C.2    Weber, R.3
  • 14
    • 1642403331 scopus 로고    scopus 로고
    • Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men
    • Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-2486.
    • (2003) AIDS , vol.17 , pp. 2479-2486
    • Mary-Krause, M.1    Cotte, L.2    Simon, A.3    Partisani, M.4    Costagliola, D.5
  • 15
    • 79959748876 scopus 로고    scopus 로고
    • Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database
    • Durand M, Sheehy O, Baril J-G, Lelorier J, Tremblay CL. Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database. J Acquir Immune Defic Syndr 2011; 57: 245-253.
    • (2011) J Acquir Immune Defic Syndr , vol.57 , pp. 245-253
    • Durand, M.1    Sheehy, O.2    Baril, J.-G.3    Lelorier, J.4    Tremblay, C.L.5
  • 16
    • 20844463037 scopus 로고    scopus 로고
    • Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS Care
    • Fichtenbaum CJ, Hadigan CM, Kotler DP etal. Treating morphologic and metabolic complications in HIV-infected patients on antiretroviral therapy. A consensus statement of an advisory committee of the International Association of Physicians in AIDS Care. IAPAC Mon 2005; 11: 38-46.
    • (2005) IAPAC Mon , vol.11 , pp. 38-46
    • Fichtenbaum, C.J.1    Hadigan, C.M.2    Kotler, D.P.3
  • 18
    • 0037456351 scopus 로고    scopus 로고
    • Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection
    • Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702-710.
    • (2003) N Engl J Med , vol.348 , pp. 702-710
    • Bozzette, S.A.1    Ake, C.F.2    Tam, H.K.3    Chang, S.W.4    Louis, T.A.5
  • 19
    • 13944282290 scopus 로고    scopus 로고
    • Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients
    • Iloeje UH, Yuan Y, L'italien G etal. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6: 37-44.
    • (2005) HIV Med , vol.6 , pp. 37-44
    • Iloeje, U.H.1    Yuan, Y.2    L'italien, G.3
  • 20
    • 77955296288 scopus 로고    scopus 로고
    • Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4
    • Lang S, Mary-Krause M, Cotte L etal. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170: 1228-1238.
    • (2010) Arch Intern Med , vol.170 , pp. 1228-1238
    • Lang, S.1    Mary-Krause, M.2    Cotte, L.3
  • 21
    • 84897372057 scopus 로고    scopus 로고
    • Prevalence and type of drug-drug interactions involving antiretrovirals in patients attending a specialist outpatient clinic in Kampala, Uganda
    • Seden K, Merry C, Lamorde M etal. Prevalence and type of drug-drug interactions involving antiretrovirals in patients attending a specialist outpatient clinic in Kampala, Uganda. J Int AIDS Soc 2012; 15: 18335.
    • (2012) J Int AIDS Soc , vol.15 , pp. 18335
    • Seden, K.1    Merry, C.2    Lamorde, M.3
  • 22
    • 80051688679 scopus 로고    scopus 로고
    • Ageing with HIV: medication use and risk for potential drug-drug interactions
    • Marzolini C, Back D, Weber R etal. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother 2011; 66: 2107-2111.
    • (2011) J Antimicrob Chemother , vol.66 , pp. 2107-2111
    • Marzolini, C.1    Back, D.2    Weber, R.3
  • 23
    • 84862169774 scopus 로고    scopus 로고
    • Using computer-based monitoring and intervention to prevent harmful combinations of antiretroviral drugs in the New York State AIDS Drug Assistance Program
    • Gonzalez CJ, Rivera CA, Martin RJ, Mergian GA, Cruz H, Agins BD. Using computer-based monitoring and intervention to prevent harmful combinations of antiretroviral drugs in the New York State AIDS Drug Assistance Program. Jt Comm J Qual Patient Saf 2012; 38: 269-276.
    • (2012) Jt Comm J Qual Patient Saf , vol.38 , pp. 269-276
    • Gonzalez, C.J.1    Rivera, C.A.2    Martin, R.J.3    Mergian, G.A.4    Cruz, H.5    Agins, B.D.6
  • 24
    • 84897402763 scopus 로고    scopus 로고
    • HIV-Druginteractions.org [Internet]. [cited Jan 20]. Available at:(accessed 2 January 2013).
    • HIV-Druginteractions.org [Internet]. [cited 2013 Jan 20]. Available at: http://www.hiv-druginteractions.org/ (accessed 2 January 2013).
    • (2013)
  • 25
    • 77953596007 scopus 로고    scopus 로고
    • Aging and HIV infection: a comparison between older HIV-infected persons and the general population
    • Onen NF, Overton ET, Seyfried W etal. Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials 2010; 11: 100-109.
    • (2010) HIV Clin Trials , vol.11 , pp. 100-109
    • Onen, N.F.1    Overton, E.T.2    Seyfried, W.3
  • 26
    • 45249121177 scopus 로고    scopus 로고
    • Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4
    • Zhou S-F. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008; 9: 310-322.
    • (2008) Curr Drug Metab , vol.9 , pp. 310-322
    • Zhou, S.-F.1
  • 27
    • 23044448423 scopus 로고    scopus 로고
    • Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs
    • Boffito M, Acosta E, Burger D etal. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir Ther (Lond) 2005; 10: 469-477.
    • (2005) Antivir Ther (Lond) , vol.10 , pp. 469-477
    • Boffito, M.1    Acosta, E.2    Burger, D.3
  • 28
    • 15244350599 scopus 로고    scopus 로고
    • Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients
    • Fellay J, Marzolini C, Decosterd L etal. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol 2005; 60: 865-873.
    • (2005) Eur J Clin Pharmacol , vol.60 , pp. 865-873
    • Fellay, J.1    Marzolini, C.2    Decosterd, L.3
  • 29
    • 0347319044 scopus 로고    scopus 로고
    • Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications
    • Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol 2004; 57: 6-14.
    • (2004) Br J Clin Pharmacol , vol.57 , pp. 6-14
    • Mangoni, A.A.1    Jackson, S.H.D.2
  • 30
    • 77954206288 scopus 로고    scopus 로고
    • Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir
    • Crawford KW, Spritzler J, Kalayjian RC etal. Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses 2010; 26: 635-643.
    • (2010) AIDS Res Hum Retroviruses , vol.26 , pp. 635-643
    • Crawford, K.W.1    Spritzler, J.2    Kalayjian, R.C.3
  • 31
    • 84865831511 scopus 로고    scopus 로고
    • A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience
    • Waters L, Patterson B, Scourfield A etal. A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience. Int J STD AIDS 2012; 23: 546-552.
    • (2012) Int J STD AIDS , vol.23 , pp. 546-552
    • Waters, L.1    Patterson, B.2    Scourfield, A.3
  • 33
    • 77953913058 scopus 로고    scopus 로고
    • Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study
    • Smith C, Sabin CA, Lundgren JD etal. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24: 1537-1548.
    • (2010) AIDS , vol.24 , pp. 1537-1548
    • Smith, C.1    Sabin, C.A.2    Lundgren, J.D.3
  • 34
    • 84907817074 scopus 로고    scopus 로고
    • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012
    • Williams I, Churchill D, Anderson J etal. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012; 13 (Suppl 2): 1-85.
    • (2012) HIV Med , vol.13 , Issue.SUPPL. 2 , pp. 1-85
    • Williams, I.1    Churchill, D.2    Anderson, J.3
  • 35
    • 84862812703 scopus 로고    scopus 로고
    • Cholesterol is associated with the presence of a lipid core in carotid plaque of asymptomatic, young-to-middle-aged African Americans with and without HIV infection and cocaine use residing in inner-city Baltimore, Md., USA
    • Du J, Wasserman BA, Tong W etal. Cholesterol is associated with the presence of a lipid core in carotid plaque of asymptomatic, young-to-middle-aged African Americans with and without HIV infection and cocaine use residing in inner-city Baltimore, Md., USA. Cerebrovasc Dis 2012; 33: 295-301.
    • (2012) Cerebrovasc Dis , vol.33 , pp. 295-301
    • Du, J.1    Wasserman, B.A.2    Tong, W.3
  • 36
    • 49849094871 scopus 로고    scopus 로고
    • Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women
    • Cook JA, Burke-Miller JK, Cohen MH etal. Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women. AIDS 2008; 22: 1355-1363.
    • (2008) AIDS , vol.22 , pp. 1355-1363
    • Cook, J.A.1    Burke-Miller, J.K.2    Cohen, M.H.3
  • 37
    • 0035198762 scopus 로고    scopus 로고
    • Principles and practice of HIV-protease inhibitor pharmacoenhancement
    • Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001; 2: 105-113.
    • (2001) HIV Med , vol.2 , pp. 105-113
    • Moyle, G.J.1    Back, D.2
  • 38
    • 0032710215 scopus 로고    scopus 로고
    • Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy
    • Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS 1999; 13: 2311-2312.
    • (1999) AIDS , vol.13 , pp. 2311-2312
    • Kakuda, T.N.1    Brundage, R.C.2    Anderson, P.L.3    Fletcher, C.V.4
  • 39
    • 17144388269 scopus 로고    scopus 로고
    • Do oestrogen receptors play a role in the pathogenesis of HIV-associated lipodystrophy?
    • Barzon L, Zamboni M, Pacenti M etal. Do oestrogen receptors play a role in the pathogenesis of HIV-associated lipodystrophy? AIDS 2005; 19: 531-533.
    • (2005) AIDS , vol.19 , pp. 531-533
    • Barzon, L.1    Zamboni, M.2    Pacenti, M.3
  • 40
    • 34447268893 scopus 로고    scopus 로고
    • Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy
    • Bonnet E, Genoux A, Bernard J, Fauvel J, Massip P, Perret B. Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy. Clin Chem Lab Med 2007; 45: 815-821.
    • (2007) Clin Chem Lab Med , vol.45 , pp. 815-821
    • Bonnet, E.1    Genoux, A.2    Bernard, J.3    Fauvel, J.4    Massip, P.5    Perret, B.6
  • 41
    • 79952335046 scopus 로고    scopus 로고
    • Plasma levels of soluble CD14 independently predict mortality in HIV infection
    • Sandler NG, Wand H, Roque A etal. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011; 203: 780-790.
    • (2011) J Infect Dis , vol.203 , pp. 780-790
    • Sandler, N.G.1    Wand, H.2    Roque, A.3
  • 42
    • 60649109560 scopus 로고    scopus 로고
    • Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients
    • Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22: F17-F24.
    • (2008) AIDS , vol.22
  • 43
    • 79958833758 scopus 로고    scopus 로고
    • Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era
    • Bedimo RJ, Westfall AO, Drechsler H, Vidiella G, Tebas P. Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era. Clin Infect Dis 2011; 53: 84-91.
    • (2011) Clin Infect Dis , vol.53 , pp. 84-91
    • Bedimo, R.J.1    Westfall, A.O.2    Drechsler, H.3    Vidiella, G.4    Tebas, P.5
  • 44
    • 84870292477 scopus 로고    scopus 로고
    • No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis
    • Ding X, Andraca-Carrera E, Cooper C etal. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 2012; 61: 441-447.
    • (2012) J Acquir Immune Defic Syndr , vol.61 , pp. 441-447
    • Ding, X.1    Andraca-Carrera, E.2    Cooper, C.3
  • 45
    • 0037202854 scopus 로고    scopus 로고
    • Protease inhibitors and cardiovascular outcomes in patients with HIV-1
    • Holmberg SD, Moorman AC, Williamson JM etal. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 1747-1748.
    • (2002) Lancet , vol.360 , pp. 1747-1748
    • Holmberg, S.D.1    Moorman, A.C.2    Williamson, J.M.3
  • 46
    • 0037103407 scopus 로고    scopus 로고
    • Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection?
    • Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 2002; 30: 471-477.
    • (2002) J Acquir Immune Defic Syndr , vol.30 , pp. 471-477
    • Klein, D.1    Hurley, L.B.2    Quesenberry Jr, C.P.3    Sidney, S.4
  • 47
    • 84861674709 scopus 로고    scopus 로고
    • A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity
    • Moyle GJ, Andrade-Villanueva J, Girard P-M etal. A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity. Antivir Ther (Lond) 2012; 17: 689-700.
    • (2012) Antivir Ther (Lond) , vol.17 , pp. 689-700
    • Moyle, G.J.1    Andrade-Villanueva, J.2    Girard, P.-M.3
  • 48
    • 0037083174 scopus 로고    scopus 로고
    • Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1
    • Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002; 185: 456-462.
    • (2002) J Infect Dis , vol.185 , pp. 456-462
    • Wolf, K.1    Tsakiris, D.A.2    Weber, R.3    Erb, P.4    Battegay, M.5
  • 49
    • 33751515147 scopus 로고    scopus 로고
    • CD4+ count-guided interruption of antiretroviral treatment
    • El-Sadr WM, Lundgren JD, Neaton JD etal. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
    • (2006) N Engl J Med , vol.355 , pp. 2283-2296
    • El-Sadr, W.M.1    Lundgren, J.D.2    Neaton, J.D.3
  • 50
    • 0037380408 scopus 로고    scopus 로고
    • Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens
    • Woerle HJ, Mariuz PR, Meyer C etal. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 2003; 52: 918-925.
    • (2003) Diabetes , vol.52 , pp. 918-925
    • Woerle, H.J.1    Mariuz, P.R.2    Meyer, C.3
  • 51
    • 10244259281 scopus 로고    scopus 로고
    • The effects of HIV protease inhibitors on carbohydrate and lipid metabolism
    • Lee GA, Rao MN, Grunfeld C. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Curr Infect Dis Rep 2004; 6: 471-482.
    • (2004) Curr Infect Dis Rep , vol.6 , pp. 471-482
    • Lee, G.A.1    Rao, M.N.2    Grunfeld, C.3
  • 52
    • 19344373051 scopus 로고    scopus 로고
    • Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study
    • Brown TT. Antiretroviral Therapy and the Prevalence and Incidence of Diabetes Mellitus in the Multicenter AIDS Cohort Study. Arch Intern Med 2005; 165: 1179-1184.
    • (2005) Arch Intern Med , vol.165 , pp. 1179-1184
    • Brown, T.T.1
  • 53
    • 0024432794 scopus 로고
    • Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid
    • Miners JO. Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid. Clin Pharmacokinet 1989; 17: 327-344.
    • (1989) Clin Pharmacokinet , vol.17 , pp. 327-344
    • Miners, J.O.1
  • 54
    • 0031265804 scopus 로고    scopus 로고
    • Lack of pharmacokinetic interaction between dipyridamole and zalcitabine in rats
    • Abobo CV, Xian Y. Lack of pharmacokinetic interaction between dipyridamole and zalcitabine in rats. Cell Mol Biol (Noisy-le-grand) 1997; 43: 1045-1050.
    • (1997) Cell Mol Biol (Noisy-le-grand) , vol.43 , pp. 1045-1050
    • Abobo, C.V.1    Xian, Y.2
  • 55
    • 35448967118 scopus 로고    scopus 로고
    • Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes
    • Janneh O, Jones E, Chandler B, Owen A, Khoo SH. Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2007; 60: 987-993.
    • (2007) J Antimicrob Chemother , vol.60 , pp. 987-993
    • Janneh, O.1    Jones, E.2    Chandler, B.3    Owen, A.4    Khoo, S.H.5
  • 56
    • 34247256797 scopus 로고    scopus 로고
    • Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
    • Farid NA, Payne CD, Small DS etal. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007; 81: 735-741.
    • (2007) Clin Pharmacol Ther , vol.81 , pp. 735-741
    • Farid, N.A.1    Payne, C.D.2    Small, D.S.3
  • 57
    • 58249135635 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
    • Collet J-P, Hulot J-S, Pena A etal. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009; 373: 309-317.
    • (2009) Lancet , vol.373 , pp. 309-317
    • Collet, J.-P.1    Hulot, J.-S.2    Pena, A.3
  • 58
    • 61449265175 scopus 로고    scopus 로고
    • Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection
    • Silverberg MJ, Leyden W, Hurley L etal. Response to newly prescribed lipid-lowering therapy in patients with and without HIV infection. Ann Intern Med 2009; 150: 301-313.
    • (2009) Ann Intern Med , vol.150 , pp. 301-313
    • Silverberg, M.J.1    Leyden, W.2    Hurley, L.3
  • 59
    • 39549093402 scopus 로고    scopus 로고
    • A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia
    • Townsend ML, Hollowell SB, Bhalodia J, Wilson KH, Kaye KS, Johnson MD. A comparison of the effectiveness of lipid-lowering therapy between HIV- and non-HIV-infected subjects with hyperlipidaemia. Int J STD AIDS 2007; 18: 851-855.
    • (2007) Int J STD AIDS , vol.18 , pp. 851-855
    • Townsend, M.L.1    Hollowell, S.B.2    Bhalodia, J.3    Wilson, K.H.4    Kaye, K.S.5    Johnson, M.D.6
  • 60
    • 79952341800 scopus 로고    scopus 로고
    • High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial
    • Ganesan A, Crum-Cianflone N, Higgins J etal. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis 2011; 203: 756-764.
    • (2011) J Infect Dis , vol.203 , pp. 756-764
    • Ganesan, A.1    Crum-Cianflone, N.2    Higgins, J.3
  • 61
    • 79960202601 scopus 로고    scopus 로고
    • Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients
    • Moore RD, Bartlett JG, Gallant JE. Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients. PLoS ONE 2011; 6: e21843.
    • (2011) PLoS ONE , vol.6
    • Moore, R.D.1    Bartlett, J.G.2    Gallant, J.E.3
  • 62
    • 0037040378 scopus 로고    scopus 로고
    • Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047
    • Internet]. Available at:
    • Fichtenbaum CJ, Gerber JG, Rosenkranz SL etal. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS [Internet]. 2002;16 (4) Available at: http://journals.lww.com/aidsonline/Fulltext/2002/03080/Pharmacokinetic_interactions_between_protease.8.aspx.
    • (2002) AIDS , vol.16 , Issue.4
    • Fichtenbaum, C.J.1    Gerber, J.G.2    Rosenkranz, S.L.3
  • 63
    • 84861830855 scopus 로고    scopus 로고
    • Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin
    • Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol 2012; 52: 922-931.
    • (2012) J Clin Pharmacol , vol.52 , pp. 922-931
    • Samineni, D.1    Desai, P.B.2    Sallans, L.3    Fichtenbaum, C.J.4
  • 64
    • 36148941342 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients
    • Van der Lee M, Sankatsing R, Schippers E etal. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients. Antivir Ther (Lond) 2007; 12: 1127-1132.
    • (2007) Antivir Ther (Lond) , vol.12 , pp. 1127-1132
    • Van der Lee, M.1    Sankatsing, R.2    Schippers, E.3
  • 66
    • 83755225761 scopus 로고    scopus 로고
    • British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals
    • Asboe D, Aitken C, Boffito M etal. British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals. HIV Med 2011; 13: 1-44.
    • (2011) HIV Med , vol.13 , pp. 1-44
    • Asboe, D.1    Aitken, C.2    Boffito, M.3
  • 67
    • 84897413604 scopus 로고    scopus 로고
    • NORVIR (Ritonavir). Summary of product characteristics. 26 August 1996 (revised 17 January 2013). Abbott Laoratories Limited, Abbott House, Maidenhead, Berkshire.
    • NORVIR (Ritonavir). Summary of product characteristics. 26 August 1996 (revised 17 January 2013). Abbott Laoratories Limited, Abbott House, Maidenhead, Berkshire.
  • 68
    • 84897422342 scopus 로고    scopus 로고
    • REYATAZ (Atazanavir sulphate). Summary of product characterstics. 2 March 2004 (revised June 2013). Bristol-Squibb Pharmaceuticals Ltd, Bristol Squibb House, Uxbridge, Middlesex.
    • REYATAZ (Atazanavir sulphate). Summary of product characterstics. 2 March 2004 (revised June 2013). Bristol-Squibb Pharmaceuticals Ltd, Bristol Squibb House, Uxbridge, Middlesex.
  • 69
    • 0024216321 scopus 로고
    • Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics
    • Abernethy DR, Gutkowska J, Lambert MD. Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics. J Cardiovasc Pharmacol 1988; 12 (Suppl 7): S67-S71.
    • (1988) J Cardiovasc Pharmacol , vol.12 , Issue.SUPPL. 7
    • Abernethy, D.R.1    Gutkowska, J.2    Lambert, M.D.3
  • 70
    • 0024463794 scopus 로고
    • The pharmacokinetic profile of amlodipine
    • Abernethy DR. The pharmacokinetic profile of amlodipine. Am Heart J 1989; 118 (5 Pt 2): 1100-1103.
    • (1989) Am Heart J , vol.118 , Issue.5 PART 2 , pp. 1100-1103
    • Abernethy, D.R.1
  • 71
    • 23444446328 scopus 로고    scopus 로고
    • Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers
    • Glesby MJ, Aberg JA, Kendall MA etal. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther 2005; 78: 143-153.
    • (2005) Clin Pharmacol Ther , vol.78 , pp. 143-153
    • Glesby, M.J.1    Aberg, J.A.2    Kendall, M.A.3
  • 74
    • 0032935655 scopus 로고    scopus 로고
    • Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes
    • Bourrié M, Meunier V, Berger Y, Fabre G. Role of cytochrome P-4502C9 in irbesartan oxidation by human liver microsomes. Drug Metab Dispos 1999; 27: 288-296.
    • (1999) Drug Metab Dispos , vol.27 , pp. 288-296
    • Bourrié, M.1    Meunier, V.2    Berger, Y.3    Fabre, G.4
  • 75
    • 0035753492 scopus 로고    scopus 로고
    • CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro
    • Hanatani T, Fukuda T, Ikeda M etal. CYP2C9*3 influences the metabolism and the drug-interaction of candesartan in vitro. Pharmacogenomics J 2001; 1: 288-292.
    • (2001) Pharmacogenomics J , vol.1 , pp. 288-292
    • Hanatani, T.1    Fukuda, T.2    Ikeda, M.3
  • 76
    • 48649085310 scopus 로고    scopus 로고
    • Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study
    • De Wit S, Sabin CA, Weber R etal. Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care 2008; 31: 1224-1229.
    • (2008) Diabetes Care , vol.31 , pp. 1224-1229
    • De Wit, S.1    Sabin, C.A.2    Weber, R.3
  • 77
    • 0042267283 scopus 로고    scopus 로고
    • A cautionary tale: fatal lactic acidosis complicating nucleoside analogue and metformin therapy
    • Worth L, Elliott J, Anderson J, Sasadeusz J, Street A, Lewin S. A cautionary tale: fatal lactic acidosis complicating nucleoside analogue and metformin therapy. Clin Infect Dis 2003; 37: 315-316.
    • (2003) Clin Infect Dis , vol.37 , pp. 315-316
    • Worth, L.1    Elliott, J.2    Anderson, J.3    Sasadeusz, J.4    Street, A.5    Lewin, S.6
  • 78
    • 33846168144 scopus 로고    scopus 로고
    • Pharmacokinetic interactions with thiazolidinediones
    • Scheen AJ. Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 2007; 46: 1-12.
    • (2007) Clin Pharmacokinet , vol.46 , pp. 1-12
    • Scheen, A.J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.